Seeking Alpha

Leerink says Jazz Pharmaceuticals (JAZZ -0.5%) shares don't reflect the positive aspects of the...

Leerink says Jazz Pharmaceuticals (JAZZ -0.5%) shares don't reflect the positive aspects of the EUSA acquisition. In particular, Leerink says that the stock hasn't adequately priced in the true earnings potential from the deal. The firm sees opportunity for investors and reiterates an Outperform rating on shares with a $68 price target.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|